Osteoclast abnormalities in fractured bone during bisphosphonate treatment for osteoporosis: a case report
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Bisphosphonates have been widely used in the treatment of an array of bone disorders. Recent complications have included unusual femoral fractures in patients who have received long term bisphosphonate treatment for osteoporosis. Although it has been shown that bisphosphonates are effective by blunting osteoclast resorption, there has been little morphologic description of the local tissue activity at the site of these unusual fractures. To evaluate for local changes to bone morphology at the fracture site in patients presenting with a bisphosphonate-related femur fracture, a sample of cortical bone was obtained at the site of a bisphosphonate fracture and was processed in a nondecalcified manner. The specimen was evaluated for potential cellular changes consistent with bisphosphonate treatment. Significant osteoclast abnormalities at the fracture site were found in a 69-year-old woman treated for 2 years with Fosamax substantiating that bone remodeling at this site is distinctly abnormal. Addressing the osteoclast dysfunction should be a focus of future therapeutic attention and intervention.
- Favus, MJ (2010) Bisphosphonates for osteoporosis. N Engl J Med 363: pp. 2027-2035 CrossRef
- Rosen CJ. Vitamin D insufficiency. N Engl J Med. 2011;364:248–53.
- Bogunovic, L, Kim, AD, Beamer, BS, Nguyen, J, Lane, JM (2010) Hypovitaminosis D in patients scheduled to undergo orthopaedic surgery. A single center analysis. J Bone Joint Surg Br 92: pp. 2300-2304 CrossRef
- Stewler, G (2004) Decimal point osteoporosis at the 10 year mark. N Engl J Med 350: pp. 1172-1174 CrossRef
- Russell, RG (2007) Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy. Ann NY Acad Med 1117: pp. 209-257 CrossRef
- Scwartz, Z (2011) Osteoconductivity of demineralized bone matrix is independent of donor bisphosphonateuse. J Bone Jt Surg 93: pp. 2278-2286 CrossRef
- Shane, E, Burr, D, Ebeling, PR, Abrahamsen, B, Adler, RA, Brown, TD (2010) Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society of Bone and Mineral Rresearch. J Bone Miner Res 25: pp. 2267-2294 CrossRef
- Allen, MR, Ginetys, E, Leeming, DJ, Burr, DB, Delmas, PD (2008) Bisphosphonates alter trabecular bone collagen cross-linking and isomerization in beagle dog vertebra. Osteoporosis Intl 19: pp. 329-337 CrossRef
- Allen, MR, Iwata, K, Phipps, R, Burr, DB (2006) Alterations in canine vertebral bone turnover, microdamge accumulation, and biochemical properties following 1 year treatment with clinical treatment doses of risedronate or alendronate. Bone 39: pp. 872-879 CrossRef
- Iwata, K, Allen, MR, Phipps, R, Burr, DB (2006) Microcrack initiation occurs more easily in vertebrae from beagles treated with alendronate than risedronate. Bone 38: pp. 42 CrossRef
- Allen, MR, Reinwald, S, Burr, DB (2008) Alendronate reduces bone toughness of ribs without significantly increasing microdamage accumulation in dogs following 3 years of daily treatment. Calcif Tissue Intl 82: pp. 354-360 CrossRef
- Forwood, MR, Burr, DB, Takano, Y, Eastman, DF, Smith, PN, Schwartz, JD (1995) Risedronate does not increase microdamage in the canine femoral neck. Bone 16: pp. 643-650 CrossRef
- Li, J, Miller, MA, Hutchins, GD, Burr, DB (2005) Imaging bone microdamage in vivo with positive positron emission tomography. Bone 37: pp. 819-824 CrossRef
- Mashiba, T, Turner, CH, Hirano, T, Forwood, MR, Johnston, CC, Burr, D (2001) Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biochemical properties in clinically relevant skeletal sites in beagles. Bone 28: pp. 524-531 CrossRef
- Mashiba, T, Hirano, T, Turner, CH, Forwood, MR, Johnston, CC, Burr, DB (2000) Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res 15: pp. 613-620 CrossRef
- Fournier, P, Boissier, S, Filleur, S, Guglielmi, J, Cabon, F, Colombel, M, Clezardin, P (2002) Bisphosphonates inhibit angiogenesis in vitro and testosterone -stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 62: pp. 6538-6544
- Hughes, D (1995) Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 10: pp. 1478-1487 CrossRef
- Coxon, H (2000) Protein geranylgeranylation is required for osteoclast formation, function and survival: inhibition by bisphosphonates and GGGTI-298. J Bone Miner Res 15: pp. 1467-1476 CrossRef
- Mautalen C, Gonzales D, Blumenfeld EL, Araujo ES, Schajowicz F. Spontaneous fractures of uninvolved bones in patients with Paget’s disease during unduly prolonged with disodium etidronate (EHDP). Clin Orthop Related Res. 1986;207:150–5.
- Al Muderis A, Azzopardi T, Cundy P. Zebra lines of pamidronate therapy in children. J Bone Joint Surg. 2007;89:1511–6.
- Armamento-Villareal R, Napoli N, Panwar V, Novack D. Suppressed bone turnover during alendronate therapy for high-turnover osteoporosis. N Engl J Med. 2006;355:2048–50.
- Dodson TB, Raje NS, Caruso PA, Rosenberg AE. Case 9-2008: a 65 year old woman with a non-healing ulcer of the jaw. N Engl J Med. 2008;358:1283–91.
- Woo S, Hande K, Richardson PG. Letter to the editor. N Engl J Med. 2005;353:100.
- Capeci, CM, Tejwani, NC (2009) Bilateral low-energy simultaneous or sequential femoral fractures in patients on long-term alendronate therapy. J Bone Joint Surg Am 91: pp. 2556-2561 CrossRef
- Das, S, Setiobudi, T, Shen, L (2010) A rational approach to management of alendronate-related subtrochanteric fractures. J Bone Joint Surg Br 92: pp. 679-686 CrossRef
- Isaacs, JD, Shidiak, L, Harris, IA, Szomor, ZL (2010) Femoral insufficiency fractures associated with prolonged bisphosphonate therapy. Clin Orthop Relat Res 468: pp. 3384-3392 CrossRef
- Lenart, B, Neviaser, A, Lyman, S, Chang, C, Edobor-Osula, F, Steele, B (2009) Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study. Osteoporos Int 20: pp. 1353-1362 CrossRef
- Odvina, CV, Levy, S, Rao, S, Zerwekh, JE, Rao, DS (2010) Unusual mid-shaft fractures during long-term bisphosphonate therapy. Clin Endocrinol 72: pp. 161-168 CrossRef
- Sayed-Noor, AS, Sjoden, G (2009) Two femoral insufficiency fractures after long term alendronate therapy. Clin Orthop Relat Res 467: pp. 1921-1926 CrossRef
- Abrahamsen, B, Eiken, P, Eastell, R (2009) Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res 24: pp. 1095-1102 CrossRef
- Giusti A, Hamdy NAT, Papapoulus SE. Atypical fractures of the femur and bisphosphonate therapy. A systemic review of case/case series studies. Bone. 2010;47:169–80.
- Black, DM, Kelly, M, Genant, HK, Palermo, L, Eastell, R, Bucci-rechtweg, C (2010) Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med 362: pp. 1761-1771 CrossRef
- Somford, M, Draijer, F, Thomassen, BJW, Chavassieux, PM, Boivin, G, Papapoulos, SE (2009) Bilateral Fractures of the Femur Diaphysis in a Patient With Rheumatoid Arthritis on Long–Term Treatment With Alendronate: Clues to the Mechanism of Increased. J Bone Miner Res 24: pp. 1736-1740 CrossRef
- Weinstein RS, Roberson PK, Manolagas SC. Giant osteoclast formation and long term oral bisphosphonate therapy. N Engl J Med. 2009 ;360:53–62.
- Osteoclast abnormalities in fractured bone during bisphosphonate treatment for osteoporosis: a case report
Volume 41, Issue 7 , pp 861-865
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Metabolic bone disease
- Industry Sectors